StreetAlpha.app
Home › Stocks › HUMA

Humacyte, Inc. (HUMA)

Healthcare
$0.45
▼ −17.90%
LAST CLOSE · NOV 20

Humacyte makes bioengineered human blood vessels, sold as Symvess, for hospitals and trauma centers. It last closed at $0.45 on Nov 20, down 17.90% on the day. The next earnings report for HUMA is expected around Thu, Mar 18, 2027. For the quarter ended Sep 2026, HUMA reported EPS of -$0.06 on revenue of $1.0M, with revenue up 36.5% from a year ago. Over its last 8 reports the stock moved an average of 16.3% the session after earnings. Over the last 12 months HUMA insiders bought $90K of stock on the open market and sold $82K, according to SEC Form 4 filings.

AI Auto Pilots
Is HUMA in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold HUMA.

Key Stats

Last 12 months
Results
Revenue
$2.4M
+52.5% vs a year ago
Net income
−$94.8M
−3955.1% margin
EPS (diluted)
−$0.45
Free cash flow
−$88.6M
−3697.0% margin
Valuation
Market cap
$123.7M
277.8M shares
P/E
–
No P/E while losing money
Price to sales
51.6
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$64.5M
At Sep 30
Debt
$36.8M
At Sep 30
Shareholder equity
$18.1M
Shares outstanding
277.8M
At Nov 10
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2024: $0$0FY2024FY2025: $2.0M$2.0MFY2025

From HUMA's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 10). Last 12 months adds up the four latest quarters.

Next report
Mar 18
Estimated date · Time not announced
Reported EPS
-$0.06
Quarter ended Sep 2026
Year ago EPS
-$0.11
Same quarter last year
Revenue
$1.0M
+36.5% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.16Dec '24Mar 2025: $0.28Mar '25Jun 2025: -$0.24Jun '25Sep 2025: -$0.11Sep '25Dec 2025: -$0.15Dec '25Mar 2026: -$0.09Mar '26Jun 2026: -$0.16Jun '26Sep 2026: -$0.06Sep '26Latest -$0.06
Revenue by quarter
Dec 2024: $0Dec '24Mar 2025: $517,000Mar '25Jun 2025: $301,000Jun '25Sep 2025: $753,000Sep '25Dec 2025: $467,000Dec '25Mar 2026: $495,000Mar '26Jun 2026: $406,000Jun '26Sep 2026: $1.0MSep '26Latest $1.0M
How HUMA moved after its last 8 reports
Average move the session after a report ±16.3%
Nov 10, 2026Time not announced+29.6%
Aug 12, 2026Time not announced−6.3%
Mar 19, 2026Time not announced−19.4%
Nov 12, 2025Time not announced−2.3%
Aug 11, 2025Time not announced−29.6%
May 13, 2025Time not announced+31.1%
Mar 28, 2025Time not announced−2.5%
Nov 8, 2024Time not announced+9.9%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on HUMAStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on HUMA
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on HUMA

Technical Analysis

HUMA · as of the Nov 20 close · updated each morning
Downtrend

The stock is 8% below its 20 day and 9% below its 50 day average. It is 72% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 45). The nearest support is the Pivot S1 at $0.42, and the nearest resistance the swing high (Oct 16) at $0.46.

Short trendBearish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityHigh, 13.9%/day
Key levels
$1.5252 week high+237.8%
$0.77200 day average+71.1%
$0.57100 day average+26.7%
$0.50Pivot R1+11.1%
$0.4950 day average+8.9%
$0.4820 day average+6.7%
$0.47Pivot+4.4%
$0.46Swing high (Oct 16)+2.2%
$0.45Last close
$0.42Pivot S1−6.7%
$0.39Swing low (Oct 26)−13.3%
$0.3452 week low−24.4%
Indicators
RSI (14)44.84Middle of its rangeNeutral
MACD0.01Below its signal lineBearish
Stochastic45.1Middle of its rangeNeutral
ADX (14)19.9No clear trend
Williams %R-76.0Oversold below −80, overbought above −20Neutral
CCI (20)-19.1Oversold below −100, overbought above 100Neutral
Rate of change−0.6%Change over 10 sessionsBearish
ATR (14)$0.06Typical daily range, 13.9% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for HUMA

What happened before

See how HUMA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow HUMA usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How HUMA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for HUMAHow many large options trades hit HUMA, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

HUMA Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ▼50 buying vs 86 selling
  • ▼Held by funds -6.8 pts
  • ▼Funds holding -34
  • ●Superinvestors: 2 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding130164−20.7%
In funds' top 1000–
Held by funds19.6%26.4%−6.8 pts
New / increased12 / 3839 / 56−47.4%
Reduced / sold out40 / 4637 / 33+22.9%
Put/call ratio0.000.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See HUMA institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

HUMA Insider Trading

All filings →
Insider trading · 12 months
Insiders are net buyers
Bought$90K5 buys · 3 insiders
Sold$82K2 sales · 2 insiders
100% of the selling was under pre-arranged trading plans.
Cluster buy: 2 insiders bought $60K between May 18 and May 19.
2026-05 bought $60K2026-05 sold $82K2026-08 bought $25K2026-09 bought $6KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Sep 14Keith Anthony JonesDirectorBuy10,000$0.56$6K
Aug 20Keith Anthony JonesDirectorBuy10,000$0.69$7K
Aug 17Keith Anthony JonesDirectorBuy30,000$0.59$18K
May 19Kathleen SebeliusDirectorBuy56,818$0.88$50K
May 18Michael T. ConstantinoDirectorBuy11,000$0.89$10K
May 18Dale A. SanderCFO and Chief Corp. Dev. OffSale plan45,887$0.90$41K
Every insider buy and sale for HUMA over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See HUMA insider trades →

From SEC Form 4 filings by HUMA's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether HUMA is in one of them and how their past HUMA trades turned out.

HUMA in the AI portfolios
Loading…

HUMA News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered HUMA in an article yet. Here's the latest on the wider market.

HUMA in the news

HUMA Congress Trades

All congress trades →
Trades, 12 months
0
Buys
0
Sells
0
People
0
Last filed Jun 14
Who traded HUMA · since 2022
Latest 5 filings of 17
$1K – $15KTraded May 3, 2024Filed Jun 14, 2024
$1K – $15KTraded May 3, 2024Filed Jun 14, 2024
Tommy TubervilleSell (partial)
$15K – $50KTraded May 3, 2024Filed Jun 14, 2024
Tommy TubervilleSell (partial)
$15K – $50KTraded May 3, 2024Filed Jun 14, 2024
Tommy TubervilleSell (partial)
$50K – $100KTraded Apr 30, 2024Filed May 15, 2024
PersonTypeAmountTradedFiledDelay
Tommy TubervilleR · ALSell$1K – $15KMay 3, 2024Jun 14, 202442 d
Tommy TubervilleR · ALSell$1K – $15KMay 3, 2024Jun 14, 202442 d
Tommy TubervilleR · ALSell (partial)$15K – $50KMay 3, 2024Jun 14, 202442 d
Tommy TubervilleR · ALSell (partial)$15K – $50KMay 3, 2024Jun 14, 202442 d
Tommy TubervilleR · ALSell (partial)$50K – $100KApr 30, 2024May 15, 202415 d

From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data

About Humacyte

Humacyte is a biotechnology company based in Durham, North Carolina, that makes bioengineered human tissues for surgical repair and replacement. Its main product is an acellular tissue engineered vessel sold under the name Symvess, which is approved in the United States as a vascular conduit for adults with arterial injury to the limbs. The company is developing additional vessels for uses such as dialysis access and peripheral artery disease. Its vessels are shipped to hospitals, trauma centers and outpatient surgical settings.

Headquarters
Durham, NC